Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Tapentadol
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Tapentadol 50mg modified-release tablets
0407020AGAAACAC
|
Tapentadol | Tapentadol | Central Nervous System | 12,889 |
|
Tapentadol 100mg modified-release tablets
0407020AGAAADAD
|
Tapentadol | Tapentadol | Central Nervous System | 10,293 |
|
Tapentadol 50mg tablets
0407020AGAAAAAA
|
Tapentadol | Tapentadol | Central Nervous System | 9,707 |
|
Tapentadol 150mg modified-release tablets
0407020AGAAAEAE
|
Tapentadol | Tapentadol | Central Nervous System | 4,204 |
|
Tapentadol 200mg modified-release tablets
0407020AGAAAFAF
|
Tapentadol | Tapentadol | Central Nervous System | 4,025 |
|
Tapentadol 250mg modified-release tablets
0407020AGAAAGAG
|
Tapentadol | Tapentadol | Central Nervous System | 1,936 |
|
Ationdo SR 50mg tablets
0407020AGBCABAC
|
Ationdo | Tapentadol | Central Nervous System | 1,154 |
|
Ationdo SR 100mg tablets
0407020AGBCACAD
|
Ationdo | Tapentadol | Central Nervous System | 1,008 |
|
Tapentadol 25mg modified-release tablets
0407020AGAAAIAI
|
Tapentadol | Tapentadol | Central Nervous System | 728 |
|
Palexia SR 50mg tablets
0407020AGBBACAC
|
Palexia | Tapentadol | Central Nervous System | 672 |
|
Tapentadol 75mg tablets
0407020AGAAABAB
|
Tapentadol | Tapentadol | Central Nervous System | 668 |
|
Palexia SR 100mg tablets
0407020AGBBADAD
|
Palexia | Tapentadol | Central Nervous System | 467 |
|
Ationdo SR 150mg tablets
0407020AGBCADAE
|
Ationdo | Tapentadol | Central Nervous System | 442 |
|
Ationdo SR 200mg tablets
0407020AGBCAEAF
|
Ationdo | Tapentadol | Central Nervous System | 407 |
|
Palexia 50mg tablets
0407020AGBBAAAA
|
Palexia | Tapentadol | Central Nervous System | 352 |
|
Palexia SR 200mg tablets
0407020AGBBAFAF
|
Palexia | Tapentadol | Central Nervous System | 264 |
|
Palexia SR 150mg tablets
0407020AGBBAEAE
|
Palexia | Tapentadol | Central Nervous System | 225 |
|
Tapentadol 20mg/ml oral solution sugar free
0407020AGAAAHAH
|
Tapentadol | Tapentadol | Central Nervous System | 222 |
|
Ationdo SR 25mg tablets
0407020AGBCAAAI
|
Ationdo | Tapentadol | Central Nervous System | 153 |
|
Ationdo SR 250mg tablets
0407020AGBCAFAG
|
Ationdo | Tapentadol | Central Nervous System | 132 |
|
Palexia SR 250mg tablets
0407020AGBBAGAG
|
Palexia | Tapentadol | Central Nervous System | 100 |
|
Palexia 20mg/ml oral solution
0407020AGBBAHAH
|
Palexia | Tapentadol | Central Nervous System | 19 |
|
Tadomon 50mg prolonged-release tablets
0407020AGBDAAAC
|
Tadomon | Tapentadol | Central Nervous System | 14 |
|
Tapentadol 50mg modified-release capsules
0407020AGAAAJAJ
|
Tapentadol | Tapentadol | Central Nervous System | 14 |
|
Palexia 75mg tablets
0407020AGBBABAB
|
Palexia | Tapentadol | Central Nervous System | 10 |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.